Etoricoxib warranted vs traditional NSAIDs in OA, RA

Author：

ISSN： 1173-5503

Source： PharmacoEconomics and Outcomes News, Vol.1, Iss.423, 2003-01, pp. : 3-4

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Etoricoxib warranted vs traditional NSAIDs in OA, RA

Inpharma, Vol. 1, Iss. 1398, 2003-01 ,pp. : 5-6

Adis International

Access to resources Recommend Favorite

Etoricoxib superior to naproxen in RA

Inpharma, Vol. 1, Iss. 1356, 2002-01 ,pp. : 10-10

Adis International

Access to resources Recommend Favorite

Celecoxib: a model therapy for RA and OA

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 277, 2000-01 ,pp. : 3-4

Adis International

Access to resources Recommend Favorite

Rofecoxib better value than NSAIDs for OA

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 337, 2001-01 ,pp. : 9-9

Adis International

Access to resources Recommend Favorite

Cost effectiveness of celecoxib, rofecoxib in OA and RA

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 352, 2002-01 ,pp. : 5-5

Adis International

Access to resources Recommend Favorite